[Coagulopathy and thrombosis: similarities and differences among pathogenic coronaviruses]

An Sist Sanit Navar. 2020 Aug 31;43(2):245-249. doi: 10.23938/ASSN.0885.
[Article in Spanish]

Abstract

One of the most significant negative prognostic factors in patients suffering from the disease caused by SARS-CoV-2 (COVID-19) is the development of coagulopathy, associated with abnormal laboratory findings, such as increased D-dimer, and venous thromboembolic complications, requiring thromboprophylactic strategies. The main clinical characteristics of COVID-19 patients are revised here as compared to other coronavirus infections, such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), emphasizing clinical, diagnostic and therapeutic aspects.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Betacoronavirus*
  • Blood Coagulation Disorders / diagnosis
  • Blood Coagulation Disorders / therapy
  • Blood Coagulation Disorders / virology*
  • COVID-19
  • Coronavirus Infections / complications
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / physiopathology
  • Coronavirus Infections / therapy
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Middle East Respiratory Syndrome Coronavirus*
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / physiopathology
  • Pneumonia, Viral / therapy
  • Prognosis
  • SARS-CoV-2
  • Severe Acute Respiratory Syndrome / complications
  • Severe Acute Respiratory Syndrome / diagnosis
  • Severe Acute Respiratory Syndrome / physiopathology
  • Severe Acute Respiratory Syndrome / therapy
  • Severe acute respiratory syndrome-related coronavirus*
  • Thrombosis / diagnosis
  • Thrombosis / therapy
  • Thrombosis / virology*

Substances

  • Fibrinolytic Agents